METHOD FOR ASSESSING CLINICAL EFFECTIVENESS IN PROSTATE CANCER Russian patent published in 2012 - IPC A61M1/36 A61B5/1455 A61K31/335 A61K35/14 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology, and may be used in treating patients with generalised prostate cancer. That is ensured by androgen blockade. Three days later, AMACR, bcl-2, bmp-7 protein levels are measured by laser disorption time-of-flight mass spectrometry. It is followed by the intravenous introduction of the mixture of autoblood 150 ml and docetaxel 80 mg incubated at 37°C for 40 minutes. In 21 days, the same amount of said mixture is introduced to total amount of docetaxel 400 mg. Five introductions of the chemopreparations are prescribed. The protein levels are measured once again. Decreasing the levels in 3-5 times testifies to the clinical effectiveness, while decreasing the protein levels less than in 3 times shows no therapeutic effect.

EFFECT: method provides the adequate assessment of the clinical effectiveness in the given pathology consistent with an adequate approach.

2 ex